0
0
GENEVA – A new report from the World Health Organization (WHO) has revealed a staggering imbalance in global medical research: less than 5% of disease-focused genomic studies are conducted in low- and middle-income countries (LMICs). This “genomic divide” means that the vast majority of modern genetic breakthroughs—which are currently paving the way for “precision medicine”—are based almost exclusively on data from populations of European ancestry.
The implications are profound. As healthcare shifts toward personalized treatments tailored to a person’s genetic makeup, billions of people across Africa, Asia, and Latin America risk being left behind, receiving treatments that were never tested for their specific genetic backgrounds.
The Geography of Genetic Data
Genomics is the study of a person’s genes (the genome), including interactions of those genes with each other and with the person’s environment. While the cost of sequencing a human genome has plummeted over the last decade, the geographical distribution of this research remains stubbornly concentrated in wealthy nations.
According to the WHO Science Council’s recent findings, the concentration of research in high-income countries (HICs) creates a “data desert” in the Global South. When scientists look for genetic markers for diseases like diabetes, heart disease, or cancer, they are essentially looking through a narrow lens that represents only a fraction of human diversity.
“We are essentially building the future of medicine on a foundation that excludes the majority of humanity,” says Dr. Soumya Swaminathan, former WHO Chief Scientist. “If we do not diversify the genomic data we collect, the ‘miracle cures’ of tomorrow will only work for the privileged few.”
Why Diversity in DNA Matters
To understand why this gap is a public health crisis, one must look at how drugs are developed. Genetic variations can influence how a person metabolizes a medication or whether they will experience a severe side effect.
For example, the blood thinner Clopidogrel (Plavix) is less effective in many people of East Asian and Pacific Islander descent due to a specific genetic variant. Because early research included these populations, doctors now know to adjust dosages or choose alternative therapies. However, for many newer “targeted” therapies, such data simply does not exist for diverse populations.
“Humanity is genetically 99.9% the same, but that 0.1% of variation accounts for significant differences in disease susceptibility and drug response,” explains Dr. Elena Rossi, a genomic epidemiologist not involved in the WHO report. “By ignoring LMICs, we aren’t just failing those populations; we are missing out on biological insights that could benefit everyone.”
Barriers to Entry: Beyond the Lab
The WHO report identifies several systemic barriers preventing LMICs from participating in the genomic revolution:
-
Infrastructure: High-tech sequencing machines require stable power grids, specialized supply chains for reagents, and high-speed internet for data transfer—utilities that are often inconsistent in resource-limited settings.
-
Bioethics and Data Sovereignty: There are growing concerns regarding “helicopter research,” where scientists from wealthy nations collect samples from developing countries, fly them back to Western labs, and patent the findings without sharing the benefits or data with the source community.
-
Workforce Training: There is a critical shortage of bioinformaticians and genetic counselors in LMICs capable of interpreting complex genomic data.
Bridging the Gap
The WHO is calling for a “Global Genomic Justice” framework. This includes a push for wealthier nations to invest in the laboratory infrastructure of LMICs and a commitment to open-science principles where data is shared transparently across borders.
Some progress is being made. Initiatives like the Human Heredity and Health in Africa (H3Africa) consortium are working to empower African scientists to lead genomic studies on the continent. However, the WHO stresses that these are exceptions to a rule of exclusion.
The Price of Inaction
The statistical context provided by the WHO is sobering. While LMICs bear a disproportionate burden of both infectious and non-communicable diseases, their genetic contribution to global databases remains negligible. This creates a feedback loop: because there is no data, there is no investment; because there is no investment, the health disparities widen.
For the average consumer, this might seem like a high-level scientific debate, but it has practical implications. In the next decade, your doctor may suggest a “pharmacogenomic” test to see which antidepressant or blood pressure medication is right for you. If you are of non-European descent, the accuracy of that test depends entirely on whether the medical community chooses to close this 95% gap today.
A Call for Balanced Progress
While the WHO report highlights a dire need for equity, some experts urge caution. Dr. Marcus Thorne, a global health policy analyst, notes that genomics should not siphon away funds from basic public health needs.
“We must be careful not to prioritize high-tech gene sequencing over clean water, vaccines, and primary care,” says Dr. Thorne. “The goal should be integration—using genomics to enhance existing public health systems, not replace them.”
As the world continues to reel from the lessons of the COVID-19 pandemic—where vaccine inequity highlighted the divide between the “haves” and “have-nots”—the WHO report serves as a timely warning. Without a concerted effort to decentralize genomic research, the next generation of medical breakthroughs may inadvertently become a tool for global inequality.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
https://health.economictimes.indiatimes.com/news/industry/under-5-of-disease-focussed-genomic-studies-conducted-in-low-middle-income-countries-who/126139035?utm_source=top_story&utm_medium=homepage
